View ValuationHumedix 将来の成長Future 基準チェック /16Humedix利益と収益がそれぞれ年間19.1%と8.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に17.6% 19%なると予測されています。主要情報19.1%収益成長率19.00%EPS成長率Pharmaceuticals 収益成長20.0%収益成長率8.9%将来の株主資本利益率17.55%アナリストカバレッジLow最終更新日24 Apr 2026今後の成長に関する最新情報Major Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.すべての更新を表示Recent updatesUpcoming Dividend • May 19Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 26 May 2026. Payment date: 15 June 2026. Trailing yield: 2.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.9%).New Risk • Apr 23New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Mar 26Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 02 April 2026. Payment date: 22 April 2026. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).お知らせ • Mar 17Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaMajor Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.Upcoming Dividend • Nov 17Upcoming dividend of ₩570 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 11 December 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.8%).New Risk • Sep 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Aug 16Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 20 August 2025. Payment date: 05 September 2025. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.0%).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Upcoming Dividend • Jun 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 22 August 2025. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.0%).Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.New Risk • May 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.お知らせ • May 08Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 5,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with SAMSUNG SECURITIES Co., Ltd. The purpose of the program is to improve shareholder value. The program will expire on November 7, 2025. As of May 6, 2025, the company had 885,401 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.New Risk • Apr 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Mar 21Upcoming dividend of ₩330 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 April 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).お知らせ • Mar 13Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Koreaお知らせ • May 25Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on November 26, 2024. As of May 23, 2024, the company had 810,507 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.Upcoming Dividend • Mar 22Upcoming dividend of ₩275 per shareEligible shareholders must have bought the stock before 29 March 2024. Payment date: 19 April 2024. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).お知らせ • Sep 28Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on March 27, 2023. As of March 15, 2022, the company had 680,117 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.お知らせ • Jun 24An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion.An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion on June 22, 2022. The transaction is resolved by the board of Humedix and expected to complete on June 30, 2022.Buying Opportunity • Mar 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.Buying Opportunity • Feb 14Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩38,700, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.Reported Earnings • May 12First quarter 2021 earnings released: EPS ₩330 (vs ₩99.00 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩28.4b (up 48% from 1Q 2020). Net income: ₩3.11b (up 215% from 1Q 2020). Profit margin: 11% (up from 5.1% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩38,850, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩35,750, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 4.6% over the past three years.お知らせ • Apr 07Humedix Co., Ltd. announced that it has received KRW 45 billion in funding from a group of investorsOn April 6, 2021, Humedix Co., Ltd. (KOSDAQ:A200670) closed the transaction.Reported Earnings • Mar 14Full year 2020 earnings released: EPS ₩1,587 (vs ₩1,094 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩98.5b (up 25% from FY 2019). Net income: ₩15.1b (up 45% from FY 2019). Profit margin: 15% (up from 13% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.分析記事 • Mar 09Humedix (KOSDAQ:200670) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Feb 20New 90-day high: ₩26,050The company is up 5.0% from its price of ₩24,800 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩26,050, the stock is trading at a trailing P/E ratio of 21.9x, up from the previous P/E ratio of 18.4x. This compares to an average P/E of 28x in the Pharmaceuticals industry in South Korea. Total return to shareholders over the past three years is a loss of 31%.分析記事 • Feb 16Humedix Co., Ltd.'s (KOSDAQ:200670) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Most readers would already be aware that Humedix's (KOSDAQ:200670) stock increased significantly by 11% over the past...分析記事 • Jan 28Should You Buy Humedix Co., Ltd. (KOSDAQ:200670) For Its Dividend?Today we'll take a closer look at Humedix Co., Ltd. ( KOSDAQ:200670 ) from a dividend investor's perspective. Owning a...Is New 90 Day High Low • Jan 18New 90-day low: ₩21,250The company is down 12% from its price of ₩24,050 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.分析記事 • Jan 11Are Humedix's (KOSDAQ:200670) Statutory Earnings A Good Reflection Of Its Earnings Potential?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...分析記事 • Dec 22What Type Of Returns Would Humedix's(KOSDAQ:200670) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...Upcoming Dividend • Dec 22Upcoming Dividend of ₩400 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.1% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.6%).分析記事 • Dec 01Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Oct 23New 90-day low: ₩23,500The company is down 17% from its price of ₩28,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩24,050The company is down 6.0% from its price of ₩25,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.業績と収益の成長予測KOSDAQ:A200670 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2027199,20042,000N/A59,000112/31/2026189,40040,100N/A50,300112/31/2025171,50051,75020,00049,800112/31/2024168,40036,90037,76753,300212/31/2023154,00029,30032,00034,000112/31/2021110,9929,0654,44119,185N/A9/30/2021115,57215,04014,22526,946N/A6/30/2021111,60015,98817,40128,724N/A3/31/2021107,72417,20410,43624,961N/A12/31/202098,48115,0846,07023,762N/A9/30/202085,72111,348-3,19914,176N/A6/30/202084,84410,717-1,45014,820N/A3/31/202080,9689,0232,61112,695N/A12/31/201978,61910,4204,46913,810N/A9/30/201973,5019,6734,69919,280N/A6/30/201968,8599,888-1,52918,138N/A3/31/201967,3519,5567,98126,417N/A12/31/201864,8329,2087,03423,803N/A9/30/201862,0179,1856,17117,454N/A6/30/201858,6709,6105,98414,378N/A3/31/201856,40111,719-5,59211,764N/A12/31/201754,72711,940-10,7328,765N/A9/30/201754,39111,385-20,9443,183N/A6/30/201751,75310,332-17,2858,250N/A3/31/201749,0519,449-17,9391,896N/A12/31/201647,13410,275-14,7897,609N/A12/31/201542,13311,62387111,706N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A200670の予測収益成長率 (年間19.1% ) は 貯蓄率 ( 3.1% ) を上回っています。収益対市場: A200670の収益 ( 19.1% ) KR市場 ( 31.5% ) よりも低い成長が予測されています。高成長収益: A200670の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: A200670の収益 ( 8.9% ) KR市場 ( 15.8% ) よりも低い成長が予測されています。高い収益成長: A200670の収益 ( 8.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A200670の 自己資本利益率 は、3年後には低くなると予測されています ( 17.6 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 20:05終値2026/05/29 00:00収益2021/12/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Humedix Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Kevin JinDaiwa Securities Co. Ltd.null nullDBS Bank LtdSang-Hun LeeiM Securities6 その他のアナリストを表示
Major Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.
Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.
Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.
Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.
Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.
Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.
Upcoming Dividend • May 19Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 26 May 2026. Payment date: 15 June 2026. Trailing yield: 2.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.9%).
New Risk • Apr 23New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Mar 26Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 02 April 2026. Payment date: 22 April 2026. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).
お知らせ • Mar 17Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
Major Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.
Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.
Upcoming Dividend • Nov 17Upcoming dividend of ₩570 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 11 December 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.8%).
New Risk • Sep 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Aug 16Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 20 August 2025. Payment date: 05 September 2025. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.0%).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Upcoming Dividend • Jun 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 22 August 2025. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.0%).
Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.
New Risk • May 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
お知らせ • May 08Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 5,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with SAMSUNG SECURITIES Co., Ltd. The purpose of the program is to improve shareholder value. The program will expire on November 7, 2025. As of May 6, 2025, the company had 885,401 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.
New Risk • Apr 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Mar 21Upcoming dividend of ₩330 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 April 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
お知らせ • Mar 13Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
お知らせ • May 25Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on November 26, 2024. As of May 23, 2024, the company had 810,507 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.
Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.
Upcoming Dividend • Mar 22Upcoming dividend of ₩275 per shareEligible shareholders must have bought the stock before 29 March 2024. Payment date: 19 April 2024. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.
Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
お知らせ • Sep 28Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on March 27, 2023. As of March 15, 2022, the company had 680,117 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.
お知らせ • Jun 24An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion.An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion on June 22, 2022. The transaction is resolved by the board of Humedix and expected to complete on June 30, 2022.
Buying Opportunity • Mar 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.
Buying Opportunity • Feb 14Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩38,700, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.
Reported Earnings • May 12First quarter 2021 earnings released: EPS ₩330 (vs ₩99.00 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩28.4b (up 48% from 1Q 2020). Net income: ₩3.11b (up 215% from 1Q 2020). Profit margin: 11% (up from 5.1% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩38,850, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩35,750, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 4.6% over the past three years.
お知らせ • Apr 07Humedix Co., Ltd. announced that it has received KRW 45 billion in funding from a group of investorsOn April 6, 2021, Humedix Co., Ltd. (KOSDAQ:A200670) closed the transaction.
Reported Earnings • Mar 14Full year 2020 earnings released: EPS ₩1,587 (vs ₩1,094 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩98.5b (up 25% from FY 2019). Net income: ₩15.1b (up 45% from FY 2019). Profit margin: 15% (up from 13% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
分析記事 • Mar 09Humedix (KOSDAQ:200670) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Feb 20New 90-day high: ₩26,050The company is up 5.0% from its price of ₩24,800 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩26,050, the stock is trading at a trailing P/E ratio of 21.9x, up from the previous P/E ratio of 18.4x. This compares to an average P/E of 28x in the Pharmaceuticals industry in South Korea. Total return to shareholders over the past three years is a loss of 31%.
分析記事 • Feb 16Humedix Co., Ltd.'s (KOSDAQ:200670) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Most readers would already be aware that Humedix's (KOSDAQ:200670) stock increased significantly by 11% over the past...
分析記事 • Jan 28Should You Buy Humedix Co., Ltd. (KOSDAQ:200670) For Its Dividend?Today we'll take a closer look at Humedix Co., Ltd. ( KOSDAQ:200670 ) from a dividend investor's perspective. Owning a...
Is New 90 Day High Low • Jan 18New 90-day low: ₩21,250The company is down 12% from its price of ₩24,050 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.
分析記事 • Jan 11Are Humedix's (KOSDAQ:200670) Statutory Earnings A Good Reflection Of Its Earnings Potential?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...
分析記事 • Dec 22What Type Of Returns Would Humedix's(KOSDAQ:200670) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩400 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.1% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.6%).
分析記事 • Dec 01Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Oct 23New 90-day low: ₩23,500The company is down 17% from its price of ₩28,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩24,050The company is down 6.0% from its price of ₩25,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.